MXPA05010483A - Cromenonindoles. - Google Patents

Cromenonindoles.

Info

Publication number
MXPA05010483A
MXPA05010483A MXPA05010483A MXPA05010483A MXPA05010483A MX PA05010483 A MXPA05010483 A MX PA05010483A MX PA05010483 A MXPA05010483 A MX PA05010483A MX PA05010483 A MXPA05010483 A MX PA05010483A MX PA05010483 A MXPA05010483 A MX PA05010483A
Authority
MX
Mexico
Prior art keywords
chromenone
indoles
derivatives
reuptake
htx
Prior art date
Application number
MXPA05010483A
Other languages
English (en)
Inventor
Schiemann Kai
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA05010483A publication Critical patent/MXPA05010483A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Los derivados de cromenonindol de la formula I (ver formula I) donde R1 R2, R3, R, A y B tienen los valores indicados en la reivindicacion 1 y sus profarmacos, derivados, solvatos, estereoisomeros y sales de aplicacion farmaceutica tienen especial efecto sobre el sistema nervioso central, sobre todo un efecto inhibidor de la reabsorcion de la 5-HT y agonista y/o antagonista de la 5-HTX. Se caracterizan por una biodisponibilidad particularmente elevada y una inhibicion particularmente fuerte de la reabsorcion de la 5-HT.
MXPA05010483A 2003-04-04 2004-03-08 Cromenonindoles. MXPA05010483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10315285A DE10315285A1 (de) 2003-04-04 2003-04-04 Chromenonindole
PCT/EP2004/002351 WO2004087692A1 (de) 2003-04-04 2004-03-08 Chromenonindole

Publications (1)

Publication Number Publication Date
MXPA05010483A true MXPA05010483A (es) 2005-11-16

Family

ID=32981019

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010483A MXPA05010483A (es) 2003-04-04 2004-03-08 Cromenonindoles.

Country Status (18)

Country Link
US (1) US7968551B2 (es)
EP (1) EP1611126B1 (es)
JP (1) JP4740114B2 (es)
KR (1) KR20050119673A (es)
CN (1) CN1768056A (es)
AR (1) AR043834A1 (es)
AT (1) ATE446959T1 (es)
AU (1) AU2004226279B2 (es)
BR (1) BRPI0408467A (es)
CA (1) CA2520892C (es)
DE (2) DE10315285A1 (es)
DK (1) DK1611126T3 (es)
ES (1) ES2335665T3 (es)
MX (1) MXPA05010483A (es)
PL (2) PL1611126T3 (es)
PT (1) PT1611126E (es)
WO (1) WO2004087692A1 (es)
ZA (1) ZA200508922B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608B (zh) * 2013-03-11 2016-06-01 天津药物研究院有限公司 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
US9598401B2 (en) 2013-07-29 2017-03-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
ATE446959T1 (de) 2009-11-15
ZA200508922B (en) 2007-02-28
PT1611126E (pt) 2010-01-29
JP2006522034A (ja) 2006-09-28
PL1611126T3 (pl) 2010-02-26
DE502004010296D1 (de) 2009-12-10
AU2004226279A1 (en) 2004-10-14
US7968551B2 (en) 2011-06-28
EP1611126B1 (de) 2009-10-28
DE10315285A1 (de) 2004-10-14
BRPI0408467A (pt) 2006-04-04
CA2520892C (en) 2012-08-21
AR043834A1 (es) 2005-08-17
DK1611126T3 (da) 2010-01-18
CA2520892A1 (en) 2004-10-14
AU2004226279B2 (en) 2010-10-28
PL377730A1 (pl) 2006-02-06
WO2004087692A1 (de) 2004-10-14
ES2335665T3 (es) 2010-03-31
JP4740114B2 (ja) 2011-08-03
KR20050119673A (ko) 2005-12-21
US20060258680A1 (en) 2006-11-16
EP1611126A1 (de) 2006-01-04
CN1768056A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
IL156873A0 (en) Pharmaceutically active piperidine derivatives
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
RS20050462A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
RS20050609A (en) Pyrazolopyridine derivatives
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
TNSN08174A1 (en) Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
MXPA05010174A (es) Derivados de indol e indolina sustituidos.
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
MXPA05010483A (es) Cromenonindoles.
MY138826A (en) 2,7-substituted indoles
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
TR200001452T2 (tr) Bifenilamidin türevleri.
BRPI0516057A (pt) derivados de indol como inibidores da ciclase de adenilato solúvel
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
AU2003281220A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal